Protagenic Therapeutics is a cutting-edge biopharmaceutical company based in New York, NY, dedicated to pioneering neuronal health through innovative and safe treatment platforms. Leveraging TCAP, a neuropeptide that has evolved over millions of years, the company aims to regulate stress response and restore healthy brain function.
With a focus on developing novel biologic compounds, Protagenic Therapeutics is building a TCAP platform set to enter clinical trials in 2022 for multiple potential indications. Their groundbreaking approach targets the cellular-level system in the brain responsible for stress mediation, offering promising solutions for a variety of unmet clinical needs in neuropsychiatric and neurodegenerative disorders.
Generated from the website